Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Core Insights - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for the prevention and treatment of hereditary angioedema (HAE) attacks [2] Group 1: Company Overview - Pharvaris aims to provide effective, well-tolerated, and easy-to-administer treatment alternatives for HAE patients, both on-demand and prophylactically [2] - The company is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate another pivotal Phase 3 study for prevention by the end of 2024 [2] Group 2: Upcoming Events - Pharvaris management will participate in the Inaugural Guggenheim Securities Healthcare Innovation Conference from November 11-13, 2024, with a fireside chat scheduled for November 13 at 9:30 a.m. ET [1] - A live audio webcast of the event will be available on the Investors section of the Pharvaris website, with a replay accessible for 30 days post-presentation [1]